The first generation of HPV vaccines, the quadrivalent HPV 6/11/16/18 and the bivalen HPV 16/18 vaccines were licensed in Europe in 2006 and 2007 resepctively. In 2015 a ninevalent HPV 6/11/16/18/31/33/45/52/58 vaccine was licensed.
A review of the current status of data and licensure and the transition process in some European countries will be evaluated. Considerations for those already fully or partially vaccinated will be described.
In the US, where the ninevalent HPV vaccine was available already at the beginning of 2015 the transition was almost accomplished in one year. For Europe it was mandatory to have data and results on the 2dose schedule, therefore the vaccine became available in May 2016. At this time the vaccine was licensed by EMA for females and males from 9 without any upper age limit, and for the 2- dose schedule. Every cycle started with the quadrivalent or bivalent vaccine could be accomplished with the ninevalent vaccine, however to get the full protection against the 5 new HPV genotypes a full course of 2 or three doses (depending on age) has to be given.
1. Joura EA, et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-23.
2. Van Damme P, et al. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine 2016;34:757-61.
3. Iversen OE, et al. Immunogenicity of the 9-Valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016;316:2411-2421.